A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Clinical trial NCT03396211 · COMPLETED
Trial details
- NCT number
- NCT03396211
- Sponsor
- Elevar Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-22
- Primary completion
- 2020-10-28
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.